Daré Bioscience, Inc. (DARE) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Daré Bioscience is a women's health biotech company transitioning from a pure R&D model to a dual-path strategy involving traditional FDA approvals and earlier market access via Section 503B compounding and consumer health products. The company operates in a single segment: Women's Health.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $2,262 | $41,691 | $6,517 | $73,431 |
| Net Loss | $(3.56) million | $(4.70) million | $(11.96) million | $1.45 million (Income) |
| Operating Expenses | $3.67 million | $4.72 million | $12.09 million | $18.14 million |
| Cash & Equivalents (End of Period) | $23.08 million | $15.70 million | $23.08 million | $11.53 million |
| Working Capital | $3.79 million | $(3.17) million | $3.79 million | $(3.17) million |
| Accumulated Deficit | $(187.25) million | $(169.78) million | $(187.25) million | $(169.78) million |
Note: Revenue consists entirely of non-cash royalty revenue related to the XACIATO license, which is offset by obligations to third parties.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 95% in Q3 and 91% YTD compared to 2024. This is due to the April 2024 sale of future royalty rights to XOMA; current revenue recognized is minimal non-cash royalty revenue payable to UiE.
- Net Loss vs. Income: The company reported a net loss of $11.96 million for the nine months ended Sept 30, 2025, compared to net income of $1.45 million in the same period in 2024. The 2024 income was driven by a one-time $20.4 million gain from the sale of royalty rights to XOMA.
- Expense Reduction: Total operating expenses decreased by 33% YTD, primarily due to a significant increase in "Contra R&D expenses" (grant funding offsets) totaling $12.6 million in the first nine months of 2025 versus $6.6 million in 2024.
- Liquidity Improvement: Cash and cash equivalents increased by $7.4 million YTD, driven by $19.7 million in net proceeds from equity issuances (ATM and Lincoln Park agreements).
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional capital. The company relies on non-dilutive grants and equity financing.
- Commercial Strategy: The company plans to launch DARE to PLAY (Sildenafil Cream) via Section 503B compounding in Q4 2025, though revenue is not expected to be material in 2025. DARE to RECLAIM (estradiol progesterone ring) is targeted for early 2027.
- Grant Funding: Significant reliance on grants from the Gates Foundation, NIH, and NICHD. A $10.0 million grant for DARE-HPV and a $10.7 million grant for Ovaprene and new contraceptive candidates are active. However, federal funding uncertainty poses a risk.
- Key Risks:
- Nasdaq Compliance: The company regained compliance with the Stockholders' Equity Rule in July 2025 but is under a mandatory one-year monitoring period. Failure to maintain compliance could lead to delisting.
- Capital Needs: Continued need for capital to fund R&D and commercialization. Future equity raises may cause dilution.
- Regulatory Uncertainty: Potential impacts of federal policy changes on FDA/NIH staffing and funding.
Investor Verification Checklist
- Grant Sustainability: Verify the status of federal grants (NIH/NICHD) given recent political uncertainty and potential funding freezes mentioned in the filing.
- Section 503B Execution: Confirm the timeline and regulatory clearance for the launch of DARE to PLAY and DARE to RECLAIM, as these are critical for near-term revenue generation.
- Capital Runway: Assess the sufficiency of the $23.1 million cash balance against the burn rate, noting that a significant portion is restricted for specific grant projects.
- Nasdaq Status: Monitor the company's stock price and equity levels to ensure continued compliance with Nasdaq listing requirements during the monitoring period.
- XACIATO Royalties: Understand that while XACIATO is commercialized, Daré receives minimal direct revenue due to the XOMA royalty purchase agreement; future upside depends on XOMA's performance exceeding $88 million in payments.